abstract
Post-vaccination uveitis is rare but has been reported during the COVID-19 pandemic. We used pharmacovigilance case/non-case studies from 1967 to 2023 to assess the association between vaccines and uveitis. We identified a significant signal of uveitis (reporting OR (ROR), 1.64; information component (IC)025, 0.66) in 1508 reports. This association is significant in women of all ages from childhood onwards. Specifically, COVID-19 messenger RNA vaccines showed the strongest imbalance signal (ROR, 5.76; IC025, 2.33), followed by hepatitis B, papillomavirus, and Ad (adenovirus) 5 vector COVID-19 vaccines. , and the flu vaccine followed. These findings highlight the importance of surveillance during the postmarketing phase to manage potential adverse events associated with vaccine administration.
Data availability statement
Data is available upon request. Research protocol and statistical code: Available from DKY (yonkkang@gmail.com). Dataset: Available from the Uppsala Surveillance Center or WHO through a data use agreement.
